ClinicalTrials.gg
CompletedNCT02419859Updated Jul 26, 2016

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

An interventional study of PaQ® Insulin Delivery Device and Insulin, Asp(B28)- in Type 2 Diabetes Mellitus, sponsored by CeQur Corporation. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-26.

Sponsored by CeQur Corporation · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 2.

Enrollment
69th of 76
20 · median 163
Started
2015
with 1 other
No phase
4 of 76
none open now
Registered
68th of 76
by date
Lead sponsor
1 of 76
CeQur Corporation

Among the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, this one is the 69th largest by enrollment, is one of 2 that started in 2015, is one of 4 with no phase, and was the 68th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 is open now. Recruiting first, the newest first:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Read the detailed description

This is a prospective, single center, open-label, uncontrolled study to assess the efficacy, safety, and patient reported outcomes of insulin delivery with PaQ® in patients with type 2 diabetes mellitus (T2DM) who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control. The patient's participation in the study is comprised of three phases: screening/baseline evaluation, transition to PaQ use and optimization, and PaQ treatment period. The use of these phases will allow an orderly transition to PaQ treatment as well as a reliable construct from which to interpret the final data.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Insulin
  • Continuous subcutaneous insulin infusion (CSII)
  • Insulin pumps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age;
  • Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage;
  • Has an ≥ 7.0% and ≤ 11.0%;
  • Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or GLP-1 agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks, (See Section 7.4 for definition of baseline basal bolus therapy);
  • Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device;
  • If on concomitant metformin, has serum creatinine \<1.5 mg/dL (male) or \<1.4 mg/dL (female);
  • If female, and of , has a negative urine pregnancy test at screening and must be using adequate means of as determined by the Investigator;
  • Is clinically euthyroid as judged by the Investigator;
  • Is able to understand and sign the required study documents and comply with the CIP requirements;
  • Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose.

Exclusion criteria

Exclusion Criteria:

  • Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator;
  • Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator;
  • Is currently taking or has taken sulfonylureas within the last 2 months;
  • Has a greater than 40 kg/m2;
  • Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months;
  • Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator;
  • Has known to skin adhesives;
  • Is female and if of , is pregnant, lactating, or planning to become pregnant;
  • Is currently being treated with or expected to require or undergo treatment with systemic by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted);
  • Currently abuses drugs or alcohol or has a history of abuse that in the Investigator's opinion would cause the individual to be non-compliant;
  • Has received any drug within 1 month;
  • Has donated blood within 30 days;
  • Has any significant medical condition (including current or past history of cardiovascular disease), laboratory findings, or medical history that in the Investigator's opinion may affect successful completion of the study and/or personal well-being;
  • Is an immediate family member (spouse, parent, child, or sibling) of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    PaQ® Insulin Delivery Device

    The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.

    Device: PaQ® Insulin Delivery Device · Drug: Insulin, Asp(B28)-

Interventions

  • DevicePaQ® Insulin Delivery Device

    PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

  • a fast-acting analog of human insulin

    Also known as: NovoRapid

06

What researchers measure

Primary outcomes

  1. Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood)

    Time frame: Change from Baseline at 12 weeks

Secondary outcomes

  1. Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood)

    Time frame: Change from Baseline at 8 weeks

  2. Fasting plasma glucose

    Time frame: Change from Baseline at 12 weeks

  3. 7-point blood glucose profiles

    Time frame: Change from Baseline at 12 weeks

  4. Total daily dose of insulin

    Time frame: Change from Baseline at 12 weeks

  5. Body weight

    Time frame: Change from Baseline at 12 weeks

  6. Barriers to Insulin Treatment questionnaire

    Measures aspects of psychological obstacles to insulin treatment in people with type 2 diabetes.

    Time frame: Change from Baseline at 12 weeks

  7. Diabetes Treatment Satisfaction Questionnaire

    Designed to make the initial assessment of total diabetes treatment satisfaction, treatment satisfaction in specific areas, and perceived frequencies of hyperglycemia and hypoglycemia.

    Time frame: Change from Baseline at 12 weeks

  8. Short form 36 Health Survey

    It is a generic measure, as opposed to disease specific, which assesses the relative burden of diseases, and differentiates the health benefits produced by a wide range of different treatments.

    Time frame: Change from Baseline at 12 weeks

  9. Adverse events

    Time frame: Collected throughout the study, average 14 weeks

  10. Hypoglycemic events

    Time frame: Collected at baseline (on current insulin therapy) and throughout the study, average 14 weeks

07

Study locations

1 site
  • Medical University of Graz
    Graz, A-8036, Austria
08

References and documents

Publications

  • Mader JK, Lilly LC, Aberer F, Poettler T, Johns D, Trautmann M, Warner JL, Pieber TR. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes. Diabet Med. 2018 Oct;35(10):1448-1456. doi: 10.1111/dme.13708. Epub 2018 Jul 5. PubMed 29888811 ↗

Individual participant data

Plan to share: Yes — No plan to share individual data sets, but will publish the results.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2015
First posted
Apr 17, 2015
Start
Feb 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
Jul 26, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02419859
Lead sponsor
CeQur Corporation
Responsible party
Sponsor
First posted
Apr 17, 2015
Start date
Feb 2015
Primary completion
Nov 2015
Completion
Nov 2015
Last update
Jul 26, 2016

Study contacts

Thomas Pieber, MD
principal investigator · Medical University of Graz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion